Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
NCT04918186Phase 2Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- May 2022
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 2, open-label trial of durvalumab, mecbotamab vedotin, ozuriftamab vedotin, ENB-003 and toripalimab in High-Grade Serous Ovarian Carcinoma (HGSOC) (3 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Objective Response Rate at 36 months. Started May 2022; status: recruiting.
02
Drugs
durvalumabmecbotamab vedotinozuriftamab vedotinENB-003toripalimab
03
Conditions
High-Grade Serous Ovarian Carcinoma (HGSOC)
Beyond the preview
Go deeper on NCT04918186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04918186.